PER-073-14已完成未知
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTSWITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- PFIZER S.A.,
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 90（—）
- 性别
- All
入选标准
- •1.Male or female patients aged 18 years or older.
- •2.Histologically confirmed, Grade 1-3a, untreated, CD20-positive follicular lymphoma (containing no elements of diffuse large B-cell lymphoma).
- •NOTE: Patients can be entered based on a diagnosis of CD20+ follicular lymphoma confirmed at the investigational site. Archival tissue must be sent to the central pathology reviewer for confirmation of diagnosis. Patients must have tissue available for the central pathology review to be enrolled.
- •(see dossier to see information complete)
排除标准
- •1. Patients who are not candidates for rituximab monoterapy
- •(see dossier for complete information)
研究者
相似试验
进行中（未招募）
1 期
A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.low tumor burden follicular lymphomaMedDRA version: 17.1 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-000132-41-HRPfizer Inc., 235 East 42nd Street, New York, NY 10017394
进行中（未招募）
1 期
A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.low tumor burden follicular lymphomaMedDRA version: 17.1 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-000132-41-GBPfizer Inc., 235 East 42nd Street, New York, NY 10017394
进行中（未招募）
1 期
A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.low tumor burden follicular lymphomaMedDRA version: 20.0 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-000132-41-PTPfizer Inc., 235 East 42nd Street, New York, NY 10017394
进行中（未招募）
1 期
A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.EUCTR2014-000132-41-ESPfizer Inc., 235 East 42nd Street, New York, NY 10017394
进行中（未招募）
1 期
A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.low tumor burden follicular lymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 100000004851EUCTR2014-000132-41-ATPfizer Inc., 235 East 42nd Street, New York, NY 10017394